Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
The main objective of this research is to develop and evaluate new PET imaging agents with high sensitivity and specificity for prostate cancer and other aggressive tumors. Specifically, the research focuses on improving upon existing prostate cancer imaging methods, such as PSA tests and PSMA PET/CT, which have limitations in sensitivity, specificity, and the ability to provide comprehensive tumor information，and aims to create a novel PET probe targeting Trop2, an antigen highly expressed in multiple cancer types, to enable in vivo, whole-tumor assessment. This would support early diagnosis, more precise staging, and effective monitoring of cancer therapy.
Key Details
Gender
MALE
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-10-01
Completion Date
2025-10-15
Last Updated
2024-12-18
Healthy Volunteers
No
Interventions
standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
Locations (1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China